CinCor Pharma, Inc. (CINC)
Price:
29.06 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
Atara Biotherapeutics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
NEWS
There's a Lot to Love About Mineralys' Valentine's Day IPO
marketbeat.com
2023-02-13 09:23:59It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volume, there certainly appears to be a lot of interest in the budding clinical-stage biopharmaceutical company.
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.
prnewswire.com
2023-01-09 22:55:00NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed acquisition of the Company by AstraZeneca PLC (NASDAQ: AZN) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $26.00 in cash for each share of CinCor common stock owned, plus a non-tradable contingent value right ("CVR") of $10.00.
Why Is CinCor (CINC) Stock Up 138% Today?
investorplace.com
2023-01-09 10:42:44CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.
AstraZeneca to acquire CinCor for US$1.8bn
proactiveinvestors.co.uk
2023-01-09 07:09:41AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued at US$522mln late September.
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
barrons.com
2023-01-09 04:32:00AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
reuters.com
2023-01-09 02:16:33AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
247wallst.com
2022-12-13 22:55:50Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
zacks.com
2022-11-29 13:32:11CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
CinCor's hypertension drug misses primary endpoint in mid-stage study
marketwatch.com
2022-11-28 08:52:23Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat.
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
globenewswire.com
2022-11-22 18:44:00WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:
These Are the 10 Best-Performing IPOs in 2022 Through October
247wallst.com
2022-11-16 21:21:59The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
CinCor Pharma to Participate at Upcoming September Investor Conferences
globenewswire.com
2022-08-31 08:00:00WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th Annual BioPharma Conference taking place September 6 - 8, 2022 in Boston, MA and Morgan Stanley's 20th Annual Healthcare Conference, taking place September 12 - 13, 2022 in New York, NY.
7 No-Brainer Biotech Stocks to Add to Your Buy List
investorplace.com
2022-06-09 09:58:13With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.
CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study
benzinga.com
2022-06-01 12:20:06CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and chronic kidney disease (CKD). The figHTN-CKD trial is a randomised Phase 2 clinical trial.
CinCor Pharma to Present at the Jefferies Healthcare Conference
globenewswire.com
2022-05-31 16:05:00WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 AM EDT.
CinCor Pharma to Present at Upcoming Investor Conferences
globenewswire.com
2022-05-17 16:05:00WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the UBS 2022 Global Healthcare Conference taking place on May 23-25 in New York, New York.
No data to display
There's a Lot to Love About Mineralys' Valentine's Day IPO
marketbeat.com
2023-02-13 09:23:59It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volume, there certainly appears to be a lot of interest in the budding clinical-stage biopharmaceutical company.
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.
prnewswire.com
2023-01-09 22:55:00NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed acquisition of the Company by AstraZeneca PLC (NASDAQ: AZN) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $26.00 in cash for each share of CinCor common stock owned, plus a non-tradable contingent value right ("CVR") of $10.00.
Why Is CinCor (CINC) Stock Up 138% Today?
investorplace.com
2023-01-09 10:42:44CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.
AstraZeneca to acquire CinCor for US$1.8bn
proactiveinvestors.co.uk
2023-01-09 07:09:41AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued at US$522mln late September.
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
barrons.com
2023-01-09 04:32:00AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
reuters.com
2023-01-09 02:16:33AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
247wallst.com
2022-12-13 22:55:50Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
zacks.com
2022-11-29 13:32:11CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
CinCor's hypertension drug misses primary endpoint in mid-stage study
marketwatch.com
2022-11-28 08:52:23Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat.
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
globenewswire.com
2022-11-22 18:44:00WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:
These Are the 10 Best-Performing IPOs in 2022 Through October
247wallst.com
2022-11-16 21:21:59The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
CinCor Pharma to Participate at Upcoming September Investor Conferences
globenewswire.com
2022-08-31 08:00:00WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th Annual BioPharma Conference taking place September 6 - 8, 2022 in Boston, MA and Morgan Stanley's 20th Annual Healthcare Conference, taking place September 12 - 13, 2022 in New York, NY.
7 No-Brainer Biotech Stocks to Add to Your Buy List
investorplace.com
2022-06-09 09:58:13With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.
CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study
benzinga.com
2022-06-01 12:20:06CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and chronic kidney disease (CKD). The figHTN-CKD trial is a randomised Phase 2 clinical trial.
CinCor Pharma to Present at the Jefferies Healthcare Conference
globenewswire.com
2022-05-31 16:05:00WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 AM EDT.
CinCor Pharma to Present at Upcoming Investor Conferences
globenewswire.com
2022-05-17 16:05:00WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the UBS 2022 Global Healthcare Conference taking place on May 23-25 in New York, New York.